SecBot SecBot
6-K ·Filed Apr 21, 2026

AZN

ASTRAZENECA PLC
BULLISH
Impact 8/10
Horizonmonths Processed6mo ago SEC0001654954-26-003757
Notable filing: 6-K
Actionable Insight ▲ Bullish

Position for potential regulatory filings and approval acceleration; monitor upcoming medical meeting presentations for detailed efficacy and safety data. Consider incremental value of Ultomiris expansion into IgAN, a high-unmet-need market with limited current therapies.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$195.77
T+0 close · Apr 21, 2026 · via day close
Latest settled
−13.52%
T+60 · $169.29
Vs SPY
−20.15%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 21 $195.77entry
  2. T+1 · 7mo ago −0.50%α −1.51% · $194.80
  3. T+5 · 7mo ago −4.73%α −5.81% · $186.51
  4. T+20 · 6mo ago −6.05%α −10.97% · $183.92
  5. T+60 · 4mo ago −13.52%α −20.15% · $169.29
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca announced positive interim results from the Phase III I CAN trial, showing that Ultomiris (ravulizumab) met its primary endpoint with a statistically significant and clinically meaningful reduction in proteinuria in adults with immunoglobulin A nephropathy (IgAN). The company plans to seek accelerated approval in key markets and present full results at a future medical meeting.

Key Facts

  • Ultomiris met the primary endpoint of statistically significant and clinically meaningful reduction in proteinuria (measured by 24-hour UPCR) at week 34 in the I CAN Phase III trial.
  • The trial enrolled approximately 510 adults with IgAN at risk of disease progression across 28 countries.
  • Ultomiris demonstrated rapid reduction in proteinuria as early as week 10.
  • The safety profile was consistent with known data, with no new safety concerns.
  • AstraZeneca plans to file for accelerated approval in key markets and present results at a forthcoming medical meeting.

Financial Impact

High potential revenue upside given the unmet need in IgAN and the drug's prior approval in other rare diseases; market opportunity supported by over 560,000 diagnosed patients in US, EU5, and Japan.

revenuepipeline valuemarket share

Risk Factors

  • Final trial results at week 106 (eGFR change) may not confirm long-term benefit.
  • Regulatory agencies may require additional data beyond the interim analysis for full approval.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-003757
Document: 0001654954-26-003757-index-headers.html0001654954-26-003757
Document: 0001654954-26-003757-index.html0001654954-26-003757
Document: 0001654954-26-003757.txt0001654954-26-003757

Track record

77 reports on AZN

Performance horizon

19 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.45 −0.59% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.45 −0.46% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.45 −0.35% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.45 −1.28% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.45 −1.18% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.45 +8.45% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.45 +6.88% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (12h)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026